The pharma company’s revenue rose 30% year-on-year to ₹965 crore from ₹743 crore in Q4FY25.
Its earnings before interest, tax, depreciation and amortisation (EBITDA) surged to ₹225 crore from ₹64 crore a year ago, while operating margin expanded sharply to 23.3% from 8.6% in the year-ago quarter.
For FY26, the company reported a turnaround with profit after tax at ₹199 crore, compared with a loss of ₹57 crore in FY25. Revenue rose 11% year-on-year to ₹3,373 crore from ₹3,033 crore, while EBITDA increased 51% to ₹630 crore. The operating margin improved to 18.7% from 13.8% a year ago.
Exceptional items for FY26 included ₹85 crore of one-time charges related to restructuring and regulatory compliance, including the impact of US entity liquidation and the new labour code.
During the quarter, the company also recognised a net charge of ₹12.7 crore towards a bankruptcy settlement, while receiving ₹35.35 crore from Dr. Reddy’s Laboratories as a full and final settlement under a business transfer agreement.
Region-wise, growth was led by the emerging markets business, where revenue surged 124% YoY in the quarter to ₹320 crore, driven by strong traction in the biotech insulin segment.
The India branded business grew 18% YoY to ₹112 crore, supported by diabetic therapies and new product introductions, while the UK market reported 20% growth to ₹349 crore.
The Irish business also saw a 12% increase in revenue during the quarter.
Wockhardt’s growth momentum was supported by product launches and pipeline progress, with 15 filings, 13 approvals and 23 product launches during the year. In biosimilars, it recorded 11 filings and 16 approvals, while its new chemical entity (NCE) portfolio saw four filings and one approval.
It also received approval for EMROK O and EMROK injection in Uganda.
The company’s biotech segment continued to be a key growth driver, with quarterly revenue rising 126% year-on-year to ₹252 crore. For the full year, biotech revenue grew 27% to ₹697 crore, aided by expansion in emerging markets and new partnerships.
Shares of Wockhardt Ltd ended 2.54% higher at ₹1,431 as the company announced the results just one minute before the market closed on Monday. The stock has gained more than 12% over the last month.
